Meningococcal Polysaccharide Conjugation via CPPT Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current meningococcal conjugate vaccines do not effectively address the increasing incidence of Neisseria meningitidis serogroup X diseases, particularly in the African Meningitis Belt, due to challenges in purification, conjugation, and formulation stability, limiting the development of a commercially viable conjugate vaccine.
Innovation Solution
A scalable and efficient conjugation process is developed for meningococcal polysaccharide serogroup X vaccines, involving polysaccharide sizing, CPPT-based activation, ADH addition, and reaction with carrier proteins in specific pH and temperature conditions, resulting in a conjugate yield of 20-30% with optimal saccharide-to-protein ratios, enabling the production of monovalent or multivalent immunogenic compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional polysaccharide conjugation methods are used for serogroup X, then the process is simple, but the conjugate yield is low and stability is poor
Solution Approach 1:
The patent applies parameter changes by optimizing conjugation conditions including pH (9.0-9.5), temperature (2-8°C), and reaction time (3-4 hours) to achieve 20-30% conjugate yield. The use of CPPT activator and controlled saccharide-to-protein ratio (0.2-0.6) further enhances yield while maintaining stability.
Solution Approach 2:
The patent uses CPPT (1-cyano-4-pyrrolidinopyridinium tetrafluoroborate) as an intermediary activator to facilitate conjugation between polysaccharide and carrier protein. This mediator enables efficient coupling while maintaining process control and achieving optimal yield.
2Speed
If polysaccharide conjugation is performed at higher temperatures, then the reaction speed increases, but the conjugate stability decreases
Solution Approach 1:
The patent changes the temperature parameter from conventional higher temperatures to a controlled range of 2-8°C, which slows the reaction but enhances conjugate stability. This parameter optimization resolves the contradiction by prioritizing stability while maintaining acceptable reaction speed through extended incubation time (3-4 hours).
3Reliability
If the saccharide-to-protein ratio is increased, then the immunogenicity improves, but the conjugate stability and purity deteriorate
Solution Approach 1:
The patent optimizes the saccharide-to-protein ratio parameter to a specific range of 0.2-0.6, which balances immunogenicity with conjugate stability and purity. This parameter control prevents excessive polysaccharide aggregation while ensuring sufficient immunogenic content.
Solution Approach 2:
The patent replaces mechanical mixing and purification methods with a chemically controlled conjugation process using CPPT activation and pH-controlled conditions, achieving better purity and stability without requiring excessive mechanical separation steps.
4Adaptability or versatility
If conventional conjugation methods are used, then the process is well-established, but they cannot effectively address serogroup X diseases in the African Meningitis Belt
Solution Approach 1:
The patent adapts conventional conjugation parameters to serogroup X specific requirements, using CPPT activator, controlled pH (9.0-9.5), and temperature (2-8°C) to achieve effective conjugation. The process maintains scalability through defined reaction conditions and standard laboratory equipment requirements.
Solution Approach 2:
The patent introduces CPPT as a specialized intermediary that enables effective conjugation for serogroup X polysaccharide, which cannot be achieved with conventional activators. This mediator provides the necessary chemical functionality for serogroup X while maintaining manufacturability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process yields stable and immunogenic meningococcal polysaccharide protein conjugates, enhancing the immunogenicity and stability of vaccines, particularly for serogroup X, which is crucial for preventing and controlling meningococcal epidemics.
Implementation Method 1
CPPT based activation of sized polysaccharide having average molecular weight between 100-150 Kda, at a pH between 9 to 9.5
Implementation Method 2
ADH addition after a duration of about 2 to 5 minutes followed by incubation period of 4-20 hrs
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The invention provides immunogenic polysaccharide protein conjugates comprising capsular polysaccharides from N. Meningitidis serogroup X and methods for preparation thereof. The present invention relates to N. meningitidis X saccharide-carrier protein conjugates prepared by a conjugation reaction. Accordingly, the instant invention relates to multivalent meningococcal polysaccharide protein conjugate composition comprising capsular saccharide from serogroups X and at least one capsular saccharide from A, C, W135 and Y wherein, i) polysaccharides A C W135 X are sized mechanically whereas polysaccharide Y is sized chemically, ii) all saccharide are conjugated to carrier protein via a linker with a cyanylation conjugation chemistry iii) all saccharide to protein ratios in final conjugates are between 0.2 - 0.6 and iv) at least two different carrier proteins selected from the group consisting of TT, DT and CRM197 are utilized.